Daratumumab binds CD38 on red blood cells (RBCs), resulting in panagglutination in blood compatibility tests. RBC transfusions and transfusion-related adverse events (AEs) from the phase 2 SIRIUS clinical trial were analyzed and, an in-depth analysis from 2 clinical study sites were performed. RBC transfusionerelated AEs, including hemolysis, were not observed among daratumumab-treated patients, confirming that transfusions may be safely administered. Introduction: Daratumumab, a human CD38 monoclonal antibody approved for multiple myeloma (MM) treatment, binds red blood cells (RBCs), resulting in panagglutination in compatibility tests. Published mitigation methods avoid additional testing, ensuring timely release of blood products. Blood transfusion management and transfusion-related outcomes of daratumumab-treated patients in the SIRIUS study are reported, with emphasis on 2 clinical sites. Patients and Methods: Patients had MM treated with ! 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or were refractory to a proteasome inhibitor and an immunomodulatory drug. RBC typing and alloantibody screening were performed in gel cards. Antibody identification using RBC panels was performed on patients with positive antibody screens. Hematology panels and serum chemistry were analyzed 2 days before each daratumumab infusion and the first daratumumab dose within each treatment cycle, respectively. Pre-and posttransfusion hemoglobin values were analyzed retrospectively. Results: At clinical cutoff, patients received 236 transfusions; 47 (37.9%) of 124 patients received 147 packed RBC transfusions, and 17 (13.7%) received 89 platelet transfusions. No hemolysis was reported, and 1 platelet transfusion reaction was observed. At Mount Sinai, no transfusion adverse events were observed, no new unexpected RBC alloantibodies were identified, and transfusions increased hemoglobin values (median, 1.2 g/dL). At Levine Cancer Institute, 6 of 7 patients responded to transfusions, with a median hemoglobin change of 1.7 g/dL. Conclusion: In SIRIUS, no RBC transfusion reactions, including hemolysis, were observed. Observations from Mount Sinai and Levine Cancer Institute confirm that transfusions may be administered safely to daratumumab-treated patients.
Introduction
CD38 is a cell-surface receptor highly expressed on multiple myeloma (MM) cells with multiple functions, including roles in signaling, receptor-mediated adhesion, and enzymatic activity. 1, 2 Daratumumab is an immunoglobulin G1 kappa (IgG1k) human monoclonal antibody targeting CD38 that has been shown to provide significant clinical benefit for the treatment of MM in patients with ! 1 prior line of therapy. 3, 4 Daratumumab-mediated antitumor activity is triggered by several CD38 immune-mediated actions (eg, complement-dependent cytotoxicity, antibodydependent cellular cytotoxicity, antibody-dependent cellular phagocytosis), apoptosis, and modulation of CD38 enzymatic activity. [5] [6] [7] Recently, daratumumab was shown to minimize the immune-suppressive functions of CD38 þ myeloid-derived suppressor cells, regulatory T cells, and regulatory B cells, and to increase T-cell clonality. 8, 9 Daratumumab is approved in the United
States and other regions for use in patients with previously treated MM as a monotherapy or in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone. [10] [11] [12] [13] Approval of daratumumab monotherapy was based on the safety and efficacy of single-agent daratumumab demonstrated in 2 clinical studies, GEN501 and SIRIUS. 14, 15 Routine blood screening in the blood bank during these studies revealed uniformly positive results from the indirect antiglobulin test (IAT) in daratumumab-treated patients. 16, 17 The IAT, also known as indirect Coombs test, is often performed to detect red blood cell (RBC) alloantibodies in plasma for compatibility before a RBC transfusion. Because CD38 is expressed on human RBCs, [18] [19] [20] daratumumab may interfere with IAT by binding to endogenous CD38 present on the surface of RBCs (Figure 1 ). 16, 17 In the treatment setting of relapsed and refractory MM, where patients are frequently anemic and often require RBC transfusions, 16, 17 Alternatively, identifying compatible blood products by phenotyping or genotyping patients before treatment with daratumumab is initiated could be implemented. 16 It was of particular interest to determine if daratumumab interference with IAT would affect the delivery and outcomes of blood transfusions in the phase 2 SIRIUS study (ClinicalTrials.gov NCT01985126). Here we provide an analysis focused specifically on RBC transfusions and transfusion-related adverse events (AEs) from the SIRIUS study and report an in-depth analysis of 2 clinical centers based on the experience of the multidisciplinary care teams for patients treated with daratumumab.
Materials and Methods

Study Design
The SIRIUS study was an open-label, 2-part, multicenter, phase 2 study conducted in the United States, Canada, and Spain, the primary results of which have been published elsewhere.
14 Briefly, part 1 of the study established the recommended dose and schedule (16 mg/kg weekly for 8 weeks, then every 2 weeks for 16 weeks, and every 4 weeks) that was used in part 2.
Patients
Eligibility criteria for the study have been published previously.
14 Briefly, patients were eligible for inclusion if they had the following: documented MM and evidence of disease progression on or within 60 days of the most recent prior treatment regimen; evidence of response to at least 1 prior treatment regimen; received at least 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or disease that was double refractory to a proteasome inhibitor and an immunomodulatory drug; and had an Eastern Cooperative Oncology Group performance status of 0 to 2. Patients were required to have a hemoglobin concentration > 75 g/L, and transfusions of packed RBCs could be administered during screening for eligibility for the study. Patients who received prior allogeneic stem-cell transplantation, those who received autologous stem-cell transplantation within 12 weeks of the first treatment cycle, or those with nonsecretory MM based on standard M-component criteria (unless baseline serum free light chain level was elevated) were excluded from participation. The protocol was approved by study site ethics committees or institutional review boards, and all patients provided written informed consent. All investigators and their research teams collected the data, and Janssen Research & Development LLC compiled the data for summation and analysis and confirmed its accuracy. Authors had full access to the study data. Additional data were collected at the 2 clinical sites and analyzed by the investigators at the Tisch Cancer Institute at the Mount Sinai School of Medicine, New York, NY, and the Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC.
Blood Typing
Patient red cell typing and unexpected RBC alloantibody screening were performed in gel cards using an automated ProVue analyzer (Ortho, Raritan, NJ). These gel cards contain dextraneacrylamide gel and a blood typing reagent (anti-A, anti-B, or anti-D) or antihuman globulin in a microtube, which allows for automated testing. Antibody identification using an RBC panel was performed on all patients with a positive antibody screen. RBC panels, including an autocontrol that tested patients' RBCs against their own plasma, were performed on all patients with a positive antibody screen using gel cards and were read manually.
Transfusion-Related Study End Points and Analyses
Hematology panels were analyzed no more than 2 days before each daratumumab infusion. Serum chemistry was analyzed no more than 2 days before the first dose of daratumumab within each 28-day treatment cycle. Pre-and posttransfusion hemoglobin values for each patient were analyzed retrospectively to determine transfusion efficacy. In addition, bilirubin, lactate dehydrogenase, and vital signs were monitored as potential indicators of transfusionrelated AEs.
Results
Transfusions in the Overall Study Population
At a clinical cutoff date of January 9, 2015, a total of 49 patients (39.5%) of the 124 patients treated with either 8 mg/kg or 16 mg/ kg of daratumumab in SIRIUS received 236 transfusions during the course of treatment (Table 1 ). Of these, 47 patients (37.9%) received a total of 147 transfusions of packed RBCs, and 17 patients (13.7%) received a total of 89 transfusions of platelets. Transfusions of whole blood or fresh frozen plasma were not administered to any patient during the time frame reported here. At the time of clinical cutoff date, only 1 transfusion-related reaction has been observed, which occurred after a platelet (not RBC) transfusion. Importantly, hemolysis, a potential outcome of administering transfusions in patients receiving an agent that binds RBCs, was not reported. No patient in SIRIUS experienced a grade 4 shift in bilirubin levels compared to baseline (data not shown).
Transfusion Experience at Clinical Study Sites
A detailed experience from 8 patients treated at Mount Sinai is presented below in conjunction with a confirmatory experience of 7 patients treated at the Levine Cancer Institute/Carolinas Healthcare System. Baseline patient demographics are shown in Table 2 .
Blood Typing. Mount Sinai Eight patients were enrolled at Mount Sinai and commenced treatment between March 4, 2014, and May 20, 2014. However, 1 of the 8 patients did not have an IAT before or after initiation of daratumumab and so is not included in the subsequent analysis.
Blood Transfusion Management
Antibody screening by IAT was performed on the other 7 patients before receiving their first daratumumab dose. Two patients showed multiple alloantibodies, including anti-D, anti-E, anti-K, anti-Jkb, anti-Fya, anti-Fyb, anti-S, and anti-Knops (Table 3) . After daratumumab treatment, all 7 patients showed agglutination of all RBCs on panel testing, with weak reactivity at the antihuman globulin phase of testing. Six of the 7 patients had a negative autocontrol, and 1 patient with a positive autocontrol had a weakly positive direct antiglobulin test with IgG. Six of the 7 patients with panagglutinin had a positive result on the first antibody screen and antibody identification panel by IAT after initiation of daratumumab, ranging from 7 to 175 days (median, 49 days). Among the 7 patients treated at Mount Sinai with IAT tests, these remained positive for a median (range) of 103 (63-190) days after discontinuing daratumumab in 5 patients. Data on the remaining 2 patients were not available.
Blood Transfusions. Mount Sinai A total of 9 leukoreduced, irradiated, phenotypically matched RBCs were provided to 3 patients during daratumumab treatment (Table 4 ). An additional 9 units were provided to 3 patients after daratumumab completion, while their IATs remained positive. Patients had a median (range) of 7 (2-44) days between pre-and posttransfusion hemoglobin measurements. All transfusions resulted in increased hemoglobin values (median, 1.2 g/dL; range, 0.5-3 g/ dL), and no associated transfusion-related AEs were observed. No patient had new unexpected RBC alloantibodies while receiving phenotypically matched RBCs. Percentages calculated with the number of subjects in each group as the denominator. Table 2 . A total of 23 transfusions were provided to 7 patients during daratumumab treatment (Table 4) . One patient did not respond to the transfusions, as indicated by no improvement in hemoglobin values. Disease progression for this patient was reported shortly after receiving packed RBCs (data not shown). The median (range) change in hemoglobin among all 7 patients was 1.7 (À0.3 to 3) g/dL.
Discussion
In the phase 2 SIRIUS study, single-agent daratumumab at 16 mg/kg showed rapid, deep, and durable responses with a clinically manageable AE profile in patients with heavily pretreated MM. Provision of blood transfusions is often required in MM patients when managing anemia, which is not only one of the symptoms of the disease itself due to marrow replacement by myeloma cells, but is also the result of a state of low erythropoietin levels in concurrent renal insufficiency (another symptom of MM), or is due to the use of myelosuppressive chemotherapy. Positive results from the IAT were observed during routine blood screening in patients treated with daratumumab. Daratumumab was subsequently found to interfere with blood bank compatibility tests, including antibody screening and full crossmatching (both by IAT) that may be part of a pretransfusion assessment. 16 To determine if daratumumab binding to RBCs may have had deleterious effects on the transfused blood that patients received in the SIRIUS study, an analysis of transfusion-related AEs in the total study population was conducted. It was found that no RBC transfusionerelated reactions, including hemolysis, were reported as AEs in patients while receiving daratumumab treatment. Analysis of potential markers of hemolysis showed that bilirubin and lactate dehydrogenase levels were not affected during the study. Further analysis from 2 clinical sites investigated the outcomes of individual patients who received blood transfusions. While the SIRIUS study was limited in not collecting all of the data prospectively, it revealed that transfusions may be provided safely to daratumumab-treated patients, including those who have received multiple units. These findings were reinforced in the patients treated at Mount Sinai who are reported here, as no daratumumabmediated, transfusion-related AEs associated with RBC transfusion were reported and no patient developed new, unexpected RBC alloantibodies while receiving phenotypically matched RBCs. Further, blood transfusions administered to daratumumab-treated patients did not result in changes to biochemical indicators of hemolysis or vital signs (data not shown). For one patient treated at Levine Cancer Institute, hemoglobin concentrations failed to increase as expected after transfusion administration, which was likely a manifestation of disease progression. This suggests that advanced disease may contribute to the lack of increased hemoglobin among patients; however, future controlled studies will be necessary to validate this concept.
Hospitals are encouraged to have processes in place to communicate the impact of blood compatibility test interference with patients, blood banks, and physicians to ensure the release of blood products in a timely manner for patients exposed to daratumumab. It is recommended that a blood type and screen be performed before daratumumab treatment begins by incorporating a type and screen and a blood bank notification into a patient's written or electronic order set immediately before the first dose of daratumumab to avoid delays in providing patients with compatible packed RBCs. 16 A simple mitigation method recommended by daratumumab's manufacturer is that patients carry identification cards listing their blood type. If a patient does not receive blood compatibility testing before receiving daratumumab, blood products can still be identified using a number of mitigation strategies, each with its own advantages and disadvantages. For example, treating reagent or donor RBCs with DTT disrupts daratumumab binding, thus allowing antibody screening and crossmatch to be performed. 16 The efficacy of the DTT method has been validated by an international Biomedical Excellence for Safer Transfusion (BEST) consortium study conducted at 25 study sites worldwide. 22 A lack of daratumumab interference with DTT-treated RBCs was reported by each site, and of the 25 sites that reported data, all 25 correctly identified a clinically significant antibody that was originally masked by daratumumab. 23, 24 While the use of DTT as an interference mitigation strategy is recognized as a practical solution, widespread implementation is an issue because, although DTT is an inexpensive reagent that is readily available, the method is time-consuming and deviates from normal laboratory procedures. 21 In addition, a limited Blood Transfusion Management number of blood group antigens, including Kell antigens, are sensitive to DTT treatment; therefore, transfusion of K-negative units is required. Similar to treatment with DTT, the use of trypsin is adopted in many institutions, although it also involves an additional laboratory procedure (unpublished observations). A 30-minute incubation with trypsin is required to remove the ectodomain of CD38 from the surface of RBCs. 16 Kell antigens are also removed by trypsin treatment. Trypsin treatment of reagent or donor RBCs to remove CD38 is not globally validated, and efforts are in place to evaluate and validate this method as an alternative to DTT treatment. CD38-deficient cord blood test cells provide an additional option for blood typing, as cord blood RBCs have very low to no expression of CD38; however, obtaining cord blood samples, particularly those that have been typed, is difficult. 21, 25 Other potential mitigation methods include the addition of anti-idiotype antibody or soluble CD38 to patient serum samples to bind daratumumab and prevent the interaction between daratumumab and RBCs and neutralize daratumumab interference. 17 While the neutralization method provides a rapid and uniform mitigation technique, it is costly, and the reagents are not widely available for use. 21 Genotyping has also been successfully used to provide blood products for transfusion to daratumumab-treated patients, and commercial kits that allow for rapid and accurate genotyping are available. 26 If performed before the administration of daratumumab or after treating reagent RBCs with DTT, phenotyping can be used to identify compatible blood products. 26 Finally, in emergency situations, patients may safely receive noncrossmatched ABO-and RhD-compatible red cells according to local blood bank practices.
Here we report on 2 clinical sites that used preinfusion phenotyping to mitigate daratumumab interference with indirect Coombs testing. This study revealed that phenotyping before daratumumab infusion and the provision of phenotypically matched RBCs for transfusion was sufficient to allow for the safe administration of blood transfusions without resulting in hemolytic AEs. The patient population eligible for daratumumab monotherapy is currently limited to heavily treated patients; however, the findings discussed here have broader implications for patient care. As therapies evolve, more patients will be treated with agents that may interfere with blood compatibility testing, making the assessment of this aspect of a new drug's mechanism of action an important point of inclusion in phase 1 clinical studies. 22 In addition, other monoclonal antibodies that target CD38, including surrogate antibodies of SAR650984 (isatuximab) and MOR202, were shown to influence blood compatibility testing, which confirms that false-positive IATs are class specific for CD38-targeting monoclonal antibodies and are not limited to daratumumab. 17 In the case of daratumumab, the drug has also shown significant clinical benefit in combination with established regimens. 3, 4 In combination with lenalidomide and dexamethasone (POLLUX study) or bortezomib and dexamethasone (CASTOR study), daratumumab achieved rapid, deep, and durable responses in patients treated with at least 1 prior therapy and reduced the risk of disease progression or death by more than 60% compared to control cohorts. 3, 4 On the basis of these large multicenter phase 3 studies (POLLUX and CASTOR), daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone was approved for the treatment of patients with MM who have received at least 1 prior therapy. 10 Encouragingly, in the POLLUX and CASTOR studies, no hemolysis was reported in patients who received blood transfusions. Since the marketing approval of daratumumab, no cases of transfusion-related hemolysis have been identified among daratumumab-treated patients, and no transfusionrelated AEs were observed during the clinical development program. 27 Thus, on the basis of the recent approval of daratumumab in combination with established treatments, dissemination of appropriate mitigation strategies is crucial. In summary, it is well recognized that daratumumab binds to CD38 on RBCs and interferes with blood bank compatibility tests; however, daratumumab interference is not clinically significant and can be easily overcome. While blood compatibility typing is now routinely performed before daratumumab treatment begins, testing can still be performed on daratumumab-treated patients using protocols that are available in the literature 16, 17 or by using genotyping to help identify blood products that are safe for transfusion. Even after daratumumab is discontinued, panagglutination may persist, and interference may continue for up to 6 months after completion of daratumumab treatment. Therefore, mitigation methods should be used until panagglutination is no longer detected. Taken together, in the treatment setting of relapsed and refractory MM where patients are treated with daratumumab and will likely require frequent RBC transfusions, blood bank and hematologist/oncologist awareness of these findings is important to minimize errors and transfusion delays.
Conclusion
In the phase 2 SIRIUS study of daratumumab monotherapy, no RBC transfusionerelated AEs, including hemolysis, were observed. These findings were reinforced in the patients treated at Mount Sinai, which confirms that transfusions may be administered safely to daratumumab-treated patients.
Clinical Practice Points
Daratumumab is a CD38-binding human monoclonal antibody that is approved as monotherapy for the treatment of heavily treated MM, and in combination with dexamethasone and lenalidomide or bortezomib as second-line therapy. Anemia is a frequent complication of MM. Daratumumab binds to CD38 that is present on RBCs, which results in panagglutination in pretransfusion blood compatibility tests. Several mitigation methods were developed to avoid unnecessary additional testing and ensure the timely release of blood products. We applied this knowledge in the management of blood transfusions in daratumumab-treated patients in the phase 2 SIRIUS study with a particular emphasis on 2 clinical study sites. Overall, in the SIRIUS study, no RBC transfusionerelated AEs, including hemolysis, were observed in daratumumab-treated patients. An in-depth analysis of patients treated at the individual sites confirmed that transfusions were safely administered. These observations support the broader experience with daratumumab; further, to date, no transfusion-related AEs or cases of hemolysis have been reported during daratumumab's clinical development program or since its marketing approval. Specific recommendations to raise awareness and aid clinical practice have been provided to patients, physicians, and blood banks. These include establishing patients' blood-compatibility profiles before treatment, requiring them to carry blood type identification cards, and identifying appropriate mitigations methods, thus enabling the safe and timely delivery of transfusions. In emergency situations, noncrossmatched ABO-and RhD-compatible RBCs may be administered according to local blood bank practices.
